Reduced cholecystokinin-like and somatostatin-like immunoreactivity in limbic lobe is associated with negative symptoms in schizophrenia

I. Nicol Ferrier, Gareth W. Roberts, Timothy J. Crow, Eve C. Johnstone, David G.C. Owens, Ying C. Lee, David O'Shaughnessy, Tom E. Adrian, Julia M. Polak, Stephen R. Bloom

Research output: Contribution to journalArticlepeer-review

146 Citations (Scopus)

Abstract

Cholecystokinin-like immunoreactivity (CCK) and somatostatin-like immunoreactivity (SRIF) were determined in fourteen brains from patients dying with a diagnosis of schizophrenia and in twelve brains from control cases. The schizophrenics had been rated during life and were divided into two groups on the basis of the presence or absence of negative symptoms (affective flattening and poverty of speech). CCK was reduced in temporal cortex of the schizophrenics and in hippocampus and amygdala of those patients with negative symptoms. SRIF was reduced in the hippocampus in samples from the latter group. The selectivity of these changes to limbic lobe may reflect the presence of a degenerative process in that area. The association of changes in hippocampus and amygdala with negative symptoms of schizophrenia suggests a separate mechanism underlying these symptoms.

Original languageEnglish
Pages (from-to)475-482
Number of pages8
JournalLife Sciences
Volume33
Issue number5
DOIs
Publication statusPublished - Aug 1 1983
Externally publishedYes

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Fingerprint

Dive into the research topics of 'Reduced cholecystokinin-like and somatostatin-like immunoreactivity in limbic lobe is associated with negative symptoms in schizophrenia'. Together they form a unique fingerprint.

Cite this